Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
somatropin + gonadotropin-releasing hormone agonist
- Development stage
- Unknown
- Lead developer
- Beilinson Medical Center
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Somatropin + gonadotropin-releasing hormone agonist is a combination therapy being investigated by the Rabin Medical Center for the treatment of boys born small for gestational age (SGA). The combination consists of recombinant human growth hormone (somatropin, specifically Norditropin) and a gonadotropin-releasing hormone (GnRH) agonist. Somatropin promotes linear growth by acting as an agonist at the growth hormone receptor, while the GnRH agonist is used to suppress the hypothalamic-pituitary-gonadal axis by downregulating GnRH receptors. This suppression delays the onset or progression of puberty, preventing the premature fusion of epiphyseal plates caused by sex steroids. By extending the duration of the growth period, the combination therapy aims to improve the final adult height of children with SGA-related growth failure compared to growth hormone treatment alone.
- Brand names
- Norditropin
- Other names
- GH + GnRHagrowth hormone and gonadotropin-releasing hormone agonist
02
Targets
GHR (Growth hormone receptor)GnRHR (Gonadotropin-releasing hormone receptor)
Beyond the preview
Go deeper on somatropin + gonadotropin-releasing hormone agonist.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on somatropin + gonadotropin-releasing hormone agonist.